Scientists Race to Test Bundibugyo Treatments as Ebola Outbreak Hits 695 Cases
Updated
Updated · The New York Times · Jun 12
Scientists Race to Test Bundibugyo Treatments as Ebola Outbreak Hits 695 Cases
1 articles · Updated · The New York Times · Jun 12
Summary
At least 695 people have been infected and 138 have died in the Bundibugyo-virus Ebola outbreak in East Africa, pushing scientists to urgently test drugs that might work.
Bundibugyo has no approved targeted treatment, leaving clinicians in eastern Congo to rely on supportive care such as rehydration, transfusions, oxygen, and close monitoring.
The gap exists because most Ebola outbreaks over the past 50 years were caused by a different species, Ebola virus, for which the WHO recommends two drugs based on clinical trials.
Those medicines cannot be assumed to work against Bundibugyo because the two viruses are evolutionarily too different, underscoring how the widening outbreak is exposing a major treatment blind spot.
With no specific cure and foreign aid cut, is East Africa facing its deadliest Ebola outbreak yet?
An untreatable Ebola strain has already crossed borders. Are travel screenings enough to protect other countries?
2026 Bundibugyo Ebola Outbreak: Rising Cases in DRC and Uganda, Global Response, and Vaccine Challenges
Overview
The Bundibugyo virus disease (BVD) outbreak is rapidly escalating in the Democratic Republic of the Congo (DRC) and has already spread into Uganda, prompting the World Health Organization to declare a global health emergency. With no approved vaccine or specific treatment available for this rare Ebola strain, the situation is urgent. As of June 6, the DRC has reported 515 confirmed cases and 91 deaths, with the outbreak marked by rising case numbers and expanding geographic spread. The lack of medical countermeasures and the cross-border transmission highlight the critical need for swift detection, isolation, and coordinated international response.